Currently out of the existing stock ratings of Matthew Sharpe, 52 are a HOLD (54.74%), 5 are a SELL (5.26%), 38 are a BUY (40%).

Matthew Sharpe

Work Performance Price Targets & Ratings Chart

Analyst Matthew Sharpe, currently employed at MORGAN STANLEY, carries an average stock price target met ratio of 89.39% that have a potential upside of 22.97% achieved within 251 days.

Matthew Sharpe’s has documented 193 price targets and ratings displayed on 13 stocks. The coverage is on Industrials, Technology, Financial Services sectors.

Most recent stock forecast was given on PL, Planet Labs PBC at 12-Jun-2023.

Wall Street Analyst Matthew Sharpe

Analyst best performing recommendations are on MAXR (MAXAR TECHNOLOGIES).
The best stock recommendation documented was for MAXR (MAXAR TECHNOLOGIES) at 12/14/2022. The price target of $42 was fulfilled within 2 days with a profit of $17.96 (74.71%) receiving and performance score of 373.54.

Average potential price target upside

BAH Booz Allen Hamilton CACI CACI International LDOS Leidos Holdings MANT ManTech International MAXR Maxar Technologies MEG Montrose Environmental Grp PAE PAE PSN Parsons Corp SAIC Science Applications International Corp PRIM Primoris Services PRSP Perspecta PL Planet Labs PBC ADS Alliance Data Systems

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 01-Apr-2026

$85

$1.87 (2.25%)

$35

6 days ago
(01-Apr-2026)

4/5 (80%)

$4.63 (5.76%)

662

Hold Since 28-May-2025

$85

$1.87 (2.25%)

$120

6 days ago
(01-Apr-2026)

9/13 (69.23%)

$4.63 (5.76%)

197

Hold Since 04-Nov-2024

$95

$16.51 (21.03%)

$190

3 months 19 days ago
(18-Dec-2025)

2/4 (50%)

$9.64 (11.29%)

72

Hold Since 18-Dec-2025

$95

$11.87 (14.28%)

$180

3 months 20 days ago
(18-Dec-2025)

10/12 (83.33%)

$9.64 (11.29%)

298

Hold Since 02-Dec-2024

$93

$9.87 (11.87%)

$119

5 months 11 days ago
(27-Oct-2025)

5/10 (50%)

$7.69 (9.01%)

202

Show more analysts

Please expand the browser size to see the chart

What Year was the first public recommendation made by Matthew Sharpe?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?